Overview

• Outlook Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors about the prospects of its lead product candidate, ONS-5010, a treatment for wet age-related macular degeneration.
• The FDA issued a complete response letter to Outlook's biologics license application for ONS-5010, citing lack of substantial evidence, unresolved manufacturing issues, and open observations from pre-approval manufacturing inspections.
• The news of the FDA's response led to a significant drop in Outlook's stock price, causing losses for investors.
• Law firms Glancy Prongay & Murray LLP, Rosen Law Firm, and Faruqi & Faruqi, LLP are reminding investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action.
• Investors who purchased Outlook securities between December 29, 2022 and August 29, 2023 are eligible to join the class action lawsuit.